tetano
Editor, Senior Moderator
Hepatol Res
. 2024 Feb 1.
doi: 10.1111/hepr.14018. Online ahead of print. Safety and effectiveness of SARS-CoV-2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire-based, cross-sectional study
Ayaka Tanifuji[SUP] 1 [/SUP], Satoko Ohfuji[SUP] 2 [/SUP], Kosuke Matsumoto[SUP] 1 [/SUP], Masanori Abe[SUP] 3 [/SUP], Atsumasa Komori[SUP] 4 [/SUP], Atsushi Takahashi[SUP] 5 [/SUP], Kazuhito Kawata[SUP] 6 [/SUP], Ken Sato[SUP] 7 [/SUP], Satoru Joshita[SUP] 8 [/SUP], Takeji Umemura[SUP] 8 [/SUP], Masayuki Ueno[SUP] 9 10 [/SUP], Nobuaki Nakayama[SUP] 11 [/SUP], Keisuke Kakisaka[SUP] 12 [/SUP], Teruko Arinaga-Hino[SUP] 13 [/SUP], Koichi Ito[SUP] 14 [/SUP], Sachiko Kanai[SUP] 15 [/SUP], Ryo Miura[SUP] 1 [/SUP], Toshihiko Arizumi[SUP] 1 [/SUP], Yoshinari Asaoka[SUP] 1 [/SUP], Takanori Ito[SUP] 16 [/SUP], Tetsuya Shimizu[SUP] 17 [/SUP], Hiroshi Yoshida[SUP] 17 [/SUP], Masayuki Ohta[SUP] 18 [/SUP], Suguru Mizuno[SUP] 11 [/SUP], Hiroyuki Isayama[SUP] 14 [/SUP], Youichi Morimoto[SUP] 9 [/SUP], Satoshi Mochida[SUP] 11 [/SUP], Hiromasa Ohira[SUP] 5 [/SUP], Atsushi Tanaka[SUP] 1 [/SUP]
Affiliations
Aim: There are few data regarding the safety and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with intractable hepatobiliary diseases. We conducted a multicenter, questionnaire-based, cross-sectional study to determine the safety and effectiveness of the SARS-CoV-2 vaccines in Japanese patients with intractable hepatobiliary disease.
Methods: Patients aged ≥18 years with autoimmune hepatitis (AIH), primary biliary cholangitis, primary sclerosing cholangitis, Budd-Chiari syndrome, idiopathic portal hypertension, and extrahepatic portal vein obstruction at each center were consecutively invited to join the study. Participants were asked to complete a questionnaire regarding their characteristics, vaccination status, post-vaccination adverse effects, and SARS-CoV-2 infection. Additionally, liver disease status, treatment regimens, and liver function test values pre- and post-vaccination were collected.
Results: The survey was conducted from September 2021 to May 2022, and 528 patients (220 AIH, 251 primary biliary cholangitis, 6 AIH- primary biliary cholangitis/primary sclerosing cholangitis overlap, 39 primary sclerosing cholangitis, 4 Budd-Chiari syndrome, 5 idiopathic portal hypertension, and 3 extrahepatic portal vein obstruction) participated in the study. Post-vaccination adverse effects were comparable to those observed in the general population. Post-vaccination liver injuries classified as grade 1 or higher were observed in 83 cases (16%), whereas grades 2 and 3 were observed in only six cases (1.1%); AIH-like liver injury requiring treatment was not observed. Overall, 12 patients (2.3%) were infected with SARS-CoV-2, and only one patient was infected 6 months after the second vaccination.
Conclusion: SARS-CoV-2 vaccines demonstrated satisfactory safety and effectiveness in Japanese patients with intractable hepatobiliary diseases.
Keywords: adverse effect; autoimmune liver disease; liver enzyme; vaccination.
. 2024 Feb 1.
doi: 10.1111/hepr.14018. Online ahead of print. Safety and effectiveness of SARS-CoV-2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire-based, cross-sectional study
Ayaka Tanifuji[SUP] 1 [/SUP], Satoko Ohfuji[SUP] 2 [/SUP], Kosuke Matsumoto[SUP] 1 [/SUP], Masanori Abe[SUP] 3 [/SUP], Atsumasa Komori[SUP] 4 [/SUP], Atsushi Takahashi[SUP] 5 [/SUP], Kazuhito Kawata[SUP] 6 [/SUP], Ken Sato[SUP] 7 [/SUP], Satoru Joshita[SUP] 8 [/SUP], Takeji Umemura[SUP] 8 [/SUP], Masayuki Ueno[SUP] 9 10 [/SUP], Nobuaki Nakayama[SUP] 11 [/SUP], Keisuke Kakisaka[SUP] 12 [/SUP], Teruko Arinaga-Hino[SUP] 13 [/SUP], Koichi Ito[SUP] 14 [/SUP], Sachiko Kanai[SUP] 15 [/SUP], Ryo Miura[SUP] 1 [/SUP], Toshihiko Arizumi[SUP] 1 [/SUP], Yoshinari Asaoka[SUP] 1 [/SUP], Takanori Ito[SUP] 16 [/SUP], Tetsuya Shimizu[SUP] 17 [/SUP], Hiroshi Yoshida[SUP] 17 [/SUP], Masayuki Ohta[SUP] 18 [/SUP], Suguru Mizuno[SUP] 11 [/SUP], Hiroyuki Isayama[SUP] 14 [/SUP], Youichi Morimoto[SUP] 9 [/SUP], Satoshi Mochida[SUP] 11 [/SUP], Hiromasa Ohira[SUP] 5 [/SUP], Atsushi Tanaka[SUP] 1 [/SUP]
Affiliations
- PMID: 38300669
- DOI: 10.1111/hepr.14018
Aim: There are few data regarding the safety and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with intractable hepatobiliary diseases. We conducted a multicenter, questionnaire-based, cross-sectional study to determine the safety and effectiveness of the SARS-CoV-2 vaccines in Japanese patients with intractable hepatobiliary disease.
Methods: Patients aged ≥18 years with autoimmune hepatitis (AIH), primary biliary cholangitis, primary sclerosing cholangitis, Budd-Chiari syndrome, idiopathic portal hypertension, and extrahepatic portal vein obstruction at each center were consecutively invited to join the study. Participants were asked to complete a questionnaire regarding their characteristics, vaccination status, post-vaccination adverse effects, and SARS-CoV-2 infection. Additionally, liver disease status, treatment regimens, and liver function test values pre- and post-vaccination were collected.
Results: The survey was conducted from September 2021 to May 2022, and 528 patients (220 AIH, 251 primary biliary cholangitis, 6 AIH- primary biliary cholangitis/primary sclerosing cholangitis overlap, 39 primary sclerosing cholangitis, 4 Budd-Chiari syndrome, 5 idiopathic portal hypertension, and 3 extrahepatic portal vein obstruction) participated in the study. Post-vaccination adverse effects were comparable to those observed in the general population. Post-vaccination liver injuries classified as grade 1 or higher were observed in 83 cases (16%), whereas grades 2 and 3 were observed in only six cases (1.1%); AIH-like liver injury requiring treatment was not observed. Overall, 12 patients (2.3%) were infected with SARS-CoV-2, and only one patient was infected 6 months after the second vaccination.
Conclusion: SARS-CoV-2 vaccines demonstrated satisfactory safety and effectiveness in Japanese patients with intractable hepatobiliary diseases.
Keywords: adverse effect; autoimmune liver disease; liver enzyme; vaccination.